Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Yzet

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Gynecologie, Obstetrique, Fertilite & Senologie|March 8, 2020
[IBD and pregnancy: From conception to birth]A Foulon, J Chevreau, C Yzet, et al.
Alimentary Pharmacology & Therapeutics|December 1, 2023
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT studyA Buisson, M Nachury, M Bazoge, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter studyM Hupé, A Streichenberger, P Wils, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Gynecologie, Obstetrique, Fertilite & Senologie|March 8, 2020
[IBD and pregnancy: From conception to birth]A Foulon, J Chevreau, C Yzet, et al.
Alimentary Pharmacology & Therapeutics|December 1, 2023
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT studyA Buisson, M Nachury, M Bazoge, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter studyM Hupé, A Streichenberger, P Wils, et al.
Pageof 1